Provided by Tiger Fintech (Singapore) Pte. Ltd.

Merck

78.97
+1.351.74%
Post-market: 79.000.0300+0.04%19:57 EDT
Volume:9.86M
Turnover:778.72M
Market Cap:198.30B
PE:11.48
High:79.49
Open:78.30
Low:78.21
Close:77.62
Loading ...

Merck & Co Inc - Zilovertamab Vedotin Achieves 56.3% Orr in Relapsed/Refractory Dlbcl

THOMSON REUTERS
·
30 May

Merck & Co. Hold Rating: Impact of Patritumab Deruxtecan Withdrawal and Future Growth Uncertainties

TIPRANKS
·
30 May

Merck & Company: Strong Buy Rating Driven by Keytruda Success and Promising Pipeline Developments

TIPRANKS
·
30 May

Merck KGaA (MKGAF) Files for Global Approval of Pimicotinib After Positive Phase III TGCT Results

Insider Monkey
·
30 May

Merck & Co. Inc. Conducted Annual Shareholders Meeting

Reuters
·
30 May

Merck & Co., Inc. (MRK) Is a Trending Stock: Facts to Know Before Betting on It

Zacks
·
29 May

Merck Withdraws Biologics License Application for Patritumab Deruxtecan

MT Newswires Live
·
29 May

Merck, Daiichi withdraw US application for 'guided missile' cancer drug

Reuters
·
29 May

Patritumab Deruxtecan Biologics License Application for Patients With Previously Treated Locally Advanced or Metastatic Egfr-Mutated Non-Small Cell Lung Cancer Voluntarily Withdrawn

THOMSON REUTERS
·
29 May

Abbisko Cayman Ltd. Secures $85M Global Commercialization Deal with Merck for Pimicotinib

Reuters
·
29 May

Heart Disease Could Be a Goner When These New Drugs Arrive -- Barrons.com

Dow Jones
·
29 May

Merck (NYSE:MRK) Declares US$0.81 Dividend for Q3 2025 Payout

Simply Wall St.
·
29 May

Nike, Travelers Share Losses Lead Dow's 118-Point Fall

Dow Jones
·
28 May

Mixed options sentiment in Merck with shares up 0.44%

TIPRANKS
·
28 May

Merck Maintains Quarterly Dividend at $0.81 Per Share; Payable July 8 to Shareholders of Record on June 16

MT Newswires Live
·
28 May

Merck & Co Inc - Declares Quarterly Dividend of $0.81 per Share for Q3 2025

THOMSON REUTERS
·
28 May

Merck Announces Third-Quarter 2025 Dividend

THOMSON REUTERS
·
28 May

Press Release: Merck Announces Third-Quarter 2025 Dividend

Dow Jones
·
28 May

Immutep announces EFTISARC-NEO Phase II trial met primary endpoint

TIPRANKS
·
27 May

BRIEF-Merck Issues Statement On Potential Reduced Dosing Recommendation For Gardasil 9

Reuters
·
24 May